Ads
related to: tamoxifen dietary restrictions
Search results
Results From The WOW.Com Content Network
Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [13] It is also being studied for other types of cancer. [13] It has been used for Albright syndrome. [14] Tamoxifen is typically taken daily by mouth for five years for breast cancer. [14]
Severe dietary restrictions such as macrobiotic diets can disrupt the body’s metabolism and cause dangerous weight loss. [28] [29] Dieting, vitamins, and other alternative treatments may interfere with the effectiveness of surgery, chemotherapy or radiation.
Tamoxifen is a pure antiestrogenic trans-isomer and has differential actions at estrogen target tissues throughout the body. Tamoxifen is selectively antiestrogenic in the breast but estrogen-like in bones and endometrial cancer. [24] Tamoxifen undergo phase I metabolism in the liver by microsomal cytochrome P450 (CYP) enzymes.
N-Desmethyltamoxifen (developmental code name ICI-55,548) is a major metabolite of tamoxifen, a selective estrogen receptor modulator (SERM). [1] [2] N-Desmethyltamoxifen is further metabolized into endoxifen (4-hydroxy-N-desmethyltamoxifen), which is thought to be the major active form of tamoxifen in the body.
The Dietary Guidelines for Americans have been criticized for recommending a diet that contains less than 2.3 grams of sodium (5.8 grams of salt/day). Notably, 95% of the world's populations have a mean intake of salt that is between 6g and 12g daily and evidence on the health effects of salt does not support such a severe restriction on salt ...
A desire to lose weight is a common motivation to change dietary habits, as is a desire to maintain an existing weight. Many weight loss diets are considered by some to entail varying degrees of health risk, and some are not widely considered to be effective.
Urinary mutagenicity is a marker of exposure to antineoplastic drugs that was first used by Falck and colleagues in 1979 and uses bacterial mutagenicity assays. Apart from being nonspecific, the test can be influenced by extraneous factors such as dietary intake and smoking and is, therefore, used sparingly.
The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial from the early 2000s designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.